Press Release: Q4 sales growth of 10.3%, 2024 business EPS guidance exceeded, and strong business EPS rebound expected in 2025
Sanofi: Q4 sales growth of 10.3%, 2024 business EPS guidance exceeded, and…
BrightSpring Health Services, Inc. Enters into Definitive Agreement to Divest Community Living Business to Sevita; Reports Preliminary 2024 Financial Results and Provides 2025 Guidance Excluding Community Living
Streamlined organization and Provider Services segment to optimize resource allocationProvider Services focus…
Santhera Receives Positive NICE Final Guidance for AGAMREE (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy
Santhera has begun launch preparations for AGAMREE® in UK with first sales…
Exosens announces 2024 estimated results above IPO guidance; 2025 guidance highlighting low twenties adjusted EBITDA growth
EXOSENS ANNOUNCES 2024 ESTIMATED RESULTS ABOVE IPO GUIDANCE; 2025 GUIDANCE HIGHLIGHTING LOW…
Teva to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results and 2025 Financial Guidance at 8 a.m. ET on January 29, 2025
December 20, 2024 16:30 ET | Source: Teva Pharmaceutical Industries Ltd TEL…